Safety and Efficacy of a 36-Week Induction Regimen of Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir in HIV-Infected Patients

REFERENCES

• Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006;41:194–200.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observa-tional study. Lancet. 2003;362:22–29.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3,2008; 1–139. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed February 10, 2009.
   Google Scholar
• Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral Treat-ment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society-USA Panel. JAMA. 2008;300:555–570.
   PubMed Web of Science ®Google Scholar
• Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov. 2003;2:624–634.
   PubMed Web of Science ®Google Scholar
• Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV infected patients with unde-tectable plasma HIV-1 RNA after triple-drug therapy. N Engl J Med. 1998;339:1261–1268.
   PubMed Web of Science ®Google Scholar
• Reijers MH, Weverling GJ, Jurriaans S, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet. 1998;352:185–190.
   PubMed Web of Science ®Google Scholar
• Pialoux G, Raffi F, Brun-Vezinet F, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indina-vir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med. 1998;339:1269–1276.
   PubMed Web of Science ®Google Scholar
• Markowitz M, Hill-Zabala C, Lang J, et al. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with aba-cavir/lamivudine/zidovudine alone in antiretroviral-naIve HIV-1 -infected patients. J Acquir Immune Defic Syndr. 2005;39:257–264.
   PubMed Web of Science ®Google Scholar
• Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacog-enomics. 2004;5:203–211.
   PubMed Web of Science ®Google Scholar
• Cao K, Hollenbach J, Shi X, Chopek M, Fernandez-Viria MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum ImmunoL 2001;62:1009–1030.
   PubMed Web of Science ®Google Scholar
• Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359(9312):1121–1122.
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screen-ing for hypersensitivity to Aabacavir. N Engl J Med 2008;358:568–579.
   PubMed Web of Science ®Google Scholar
• Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-B5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46:1111–1117.
   PubMed Web of Science ®Google Scholar
• Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretrovi-ral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2008;47:266–285.
   PubMed Web of Science ®Google Scholar
• Sax P, Tierney C, Collier A, et al. Abacavir-lamivudine ver-sus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;23:2230–2240.
   Web of Science ®Google Scholar
• Young B, Squires K, Patel P, et al. First large, multi-center, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS. 2008;22:1673-1675.
   Google Scholar
• Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48. AIDS. 2008;22:1389–1397.
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricit-abine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646–655.
   PubMed Web of Science ®Google Scholar
• Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the base-line CD4 cell count and viral load. J Am Med Assoc. 2001;286:2560–2567.
   PubMed Web of Science ®Google Scholar
• Ha B, Liao Q, Dix L, Pappa K. Firologic response and safety of the abacavir/lamivudine fixed-dose formulation as part of highly active antiretroviral therapy: analysis of six clinical studies. HIV Clin Trials. 2009;10(2):65–75.
   PubMed Web of Science ®Google Scholar
• Elion R, DeJesus E, Sension M, et al. Once-daily abacavir/ lamivudine and ritonavir-boosted atazanavir for the treat-ment of HIV-1 infection in antiretroviral-naive patients: a 48 week pilot study. HIV Clin Trials. 2008:9(3):152–163.
   PubMed Web of Science ®Google Scholar